HOME PRODUCTS COMPANY CONTACT FAQ

Research Dictionary Pharma

Sign Up FREE or Login

arginyl-leucyl-tyrosyl-glutamic acid

has antiangiogenic activity

Also Known As:

Arg-Leu-Tyr-Glu

Networked: 5 relevant articles (0 outcomes, 1 trials/studies)

Bio-Agent Context: Research Results

Amino Acids, Peptides, and Proteins: 1
- Peptides: 82426
  - Oligopeptides: 519
    - arginyl-leucyl-tyrosyl-glutamic acid: 5

Experts

1.	Kim, Young-Myeong: 5 articles (04/2021 - 02/2017)
2.	Baek, Yi-Yong: 4 articles (04/2021 - 02/2017)
3.	Ha, Kwon-Soo: 4 articles (02/2021 - 02/2017)
4.	Kim, Joohwan: 4 articles (02/2021 - 02/2017)
5.	Kim, Taesam: 4 articles (02/2021 - 02/2017)
6.	Kwon, Young-Guen: 4 articles (02/2021 - 02/2017)
7.	Park, Wonjin: 4 articles (02/2021 - 02/2017)
8.	Choi, Seunghwan: 3 articles (02/2021 - 01/2019)
9.	Kim, Suji: 3 articles (02/2021 - 01/2019)
10.	Park, Minsik: 3 articles (02/2021 - 01/2019)

Related Diseases

1.	Choroidal Neovascularization 01/01/2019 - "This study was undertaken to evaluate the therapeutic mechanisms and effects of the tetrapeptide Arg-Leu-Tyr-Glu (RLYE), a VEGFR2 inhibitor, in the development of vascular permeability and choroidal neovascularization (CNV). " 04/09/2021 - "It has been shown previously that a novel tetrapeptide, Arg-Leu-Tyr-Glu (RLYE), derived from human plasminogen inhibits vascular endothelial growth factor (VEGF)-induced angiogenesis, suppresses choroidal neovascularization in mice by an inhibition of VEGF receptor-2 (VEGFR-2) specific signaling pathway. " 01/01/2019 - "Arg-Leu-Tyr-Glu Suppresses Retinal Endothelial Permeability and Choroidal Neovascularization by Inhibiting the VEGF Receptor 2 Signaling Pathway."
2.	Colorectal Neoplasms (Colorectal Cancer) 12/01/2019 - "The tetrapeptide Arg-Leu-Tyr-Glu (RLYE), a vascular endothelial growth factor (VEGF) receptor-2 antagonist, has been used previously either alone or in combination with chemotherapeutic drugs for treating colorectal cancer in a mouse model. "
3.	Neoplasms (Cancer) 02/14/2017 - "Arg-Leu-Tyr-Glu tetrapeptide inhibits tumor progression by suppressing angiogenesis and vascular permeability via VEGF receptor-2 antagonism."
4.	Diabetic Retinopathy (Retinopathy, Diabetic) 02/01/2021 - "We examined the therapeutic effect of recently developed N-acetylated Arg-Leu-Tyr-Glu (Ac-RLYE), a human plasminogen kringle-5 domain-derived VEGFR-2 antagonists, on the pathogenesis of diabetic retinopathy. "

Related Drugs and Biologics

1.	Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)
2.	Plasminogen
3.	Therapeutic Uses
4.	Vascular Endothelial Growth Factor Receptor-2 (Vascular Endothelial Growth Factor Receptor 2)
5.	Vascular Endothelial Growth Factor Receptors (VEGF Receptors)
6.	Retinaldehyde (Retinal)